hat
Jijman an premye konpare 12 semèn nan tretman Vosevi ak plasebo nan adilt ki gen genotype 1 ki te deja echwe tretman ak yon dwòg NS5A inibitè. Pasyan ki gen jenotip 2, 3, 4, 5 oswa 6 tout te resevwa Vosevi.
eng
The first trial compared 12 weeks of Vosevi treatment with placebo in adults with genotype 1 who had previously failed treatment with an NS5A inhibitor drug. Patients with genotypes 2, 3, 4, 5 or 6 all received Vosevi.